Kura Oncology (KURA) EBT Margin (2025 - 2026)
Kura Oncology's (KURA) quarterly EBT Margin came in at 401.45% in Q1 2026, up 401.0% year-on-year from 80.13% in Q1 2025, and up 14.0% on a QoQ basis from 466.82% in Q4 2025.
Kura Oncology (KURA) EBT Margin (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has 2 years of EBT Margin data on file, last reported at 401.45% in Q1 2026.
- On a quarterly basis, EBT Margin rose 401.0% year-over-year to 401.45% in Q1 2026; TTM through Mar 2026 was 411.08%, a N/A change from a year earlier, with the FY2025 full-year figure at 412.51%, changed N/A from the prior year.
- EBT Margin for Q1 2026 stood at 401.45%, up from 466.82% in the prior quarter.
- Over the last five years, EBT Margin for KURA reached as high as 357.19% in Q3 2025 and fell as low as 466.82% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Kura Oncology | 925.97 Mn | 925.97 Mn | 18.00 Mn | -401.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -401.45% |
| Dec 31, 2025 | -466.82% |
| Sep 30, 2025 | -357.19% |
| Jun 30, 2025 | -432.51% |
| Mar 31, 2025 | -405.46% |